Low-Dose Intrathecal Ziconotide for Spasticity From Primary Lateral Sclerosis: A Case Report.
A A Pract
; 13(1): 31-33, 2019 Jul 01.
Article
em En
| MEDLINE
| ID: mdl-31260413
ABSTRACT
Spasticity can be very debilitating and painful. We present a case of severe spasticity from primary lateral sclerosis refractory to intrathecal baclofen in doses up to 1100 µg/d. Baclofen was weaned down and switched to intrathecal ziconotide at 0.6 µg/d. The dose was then titrated up to 3 µg/d with excellent control of spasticity. This case suggests that low-dose intrathecal ziconotide should be considered in patients with lower extremity spasticity refractory to intrathecal baclofen.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Dor
/
Doença dos Neurônios Motores
/
ômega-Conotoxinas
/
Espasticidade Muscular
Idioma:
En
Ano de publicação:
2019
Tipo de documento:
Article